Weekly Recap: Ligand (LGND) $47M AvenCell funding and EMEA Ryjunea royalties

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is boosting its biopharma reach—financing AvenCell with up to $47M tied to AVC-201/AVC-203 royalties while securing EMEA royalties for Ryjunea, investing in Primrose Bio, and drawing an Overweight start from Barclays at $345.Previous Week RecapThis…